Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Athens – page 5

973 clinical trials in Athens, Greece across 13 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Athens at a glance
973
clinical trials
  • Research sites13
Type of trial
Recruitment status
Quick filters

973 trials in Athens

Open in trial search

Study on the Effectiveness of Abelacimab for High-Risk Atrial Fibrillation Patients Unsuitable for Oral Anticoagulation

Investigational
Countries:GreeceGreece
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Hepatic cirrhosis+2

Recruiting

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin
  • Sponsor:Akero Therapeutics Inc.

Study of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Eli Lilly & Co.

Study on the Safety and Effectiveness of GSK5733584 with Dostarlimab and Carboplatin for Patients with Advanced Gynecological Tumors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Adjuvant Therapy with RO7435846 (divarasib) versus Pembrolizumab or Nivolumab or Observation in Patients After Surgery for Stage II‑III KRAS G12C NSCLC

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Divarasib
  • Sponsor:F. Hoffmann-La Roche AG

A study of MK-1084 and pembrolizumab for patients with resected KRAS G12C-mutant non-small cell lung cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Rinatabart Sesutecan with or without bevacizumab versus standard platinum‑based chemotherapy drug combination in patients with recurrent platinum‑sensitive ovarian cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Genmab A/S

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

A Phase 2/3 Randomized Double‑Blind Study of Inebilizumab for Safety and Tolerability in Patients with Autoimmune Hepatitis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Phase 3 Study of Subcutaneous vs Intravenous Tarlatamab with Siltuximab in Relapsed Extensive-Stage Small Cell Lung Cancer after Platinum Chemotherapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Siltuximab
  • Sponsor:Amgen Inc.

Study of belumosudil versus drug combination in patients aged 12 years and older with chronic graft‑versus‑host disease refractory after prior therapy

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Neoplasm

Recruiting

Long‑term Safety of Adagrasib with Drug Combination in Adults with Solid Tumors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Greece

The busiest research cities in the country

All 50 cities in Greece

Clinical research in Athens

What the registry says about research in the country

01 Oncology Studies

Clinical trials focusing on head and neck cancer, bladder cancer, and advanced solid tumors. Research includes innovative combination therapies and novel treatment approaches for various tumor types.

  • Head & Neck Squamous Cell Carcinoma
  • Bladder Cancer Treatment
  • Gynecological Tumors

Studies evaluate new therapeutic combinations and their impact on patient survival rates.

02 Autoimmune Conditions

Investigations into treatments for various autoimmune disorders, including Sjögren's Syndrome, lupus, and inflammatory conditions.

  • Cutaneous Lupus Erythematosus
  • Plaque Psoriasis
  • Inflammatory Bowel Diseases

Focus on developing targeted therapies for chronic autoimmune conditions.

03 Cardiovascular & Metabolic

Research examining treatments for heart failure, cardiovascular disease prevention, and metabolic disorders including obesity.

  • Heart Failure Prevention
  • Chronic Kidney Disease
  • Obesity Management

Trials evaluating new therapeutic approaches for cardiovascular risk reduction.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.